# Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

> **NCT01977755** · PHASE2 · COMPLETED · sponsor: **Zealand Pharma** · enrollment: 591 (actual)

## Conditions studied

- Focus of Study is STEMI

## Interventions

- **DRUG:** danegaptide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01977755
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-12-20
- **Final completion:** 2016-06-08
- **Target enrollment:** 591 (ACTUAL)
- **Last updated:** 2018-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01977755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01977755, "Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01977755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*